New treatment for triple negative breast cancer - GLUT1 inhibitor.

Triple-negative breast cancer (TNBC) is named for negative expressions of estrogen lipoly (ER), progesterone lipoly (PR) and human skin growth factor 2 (HER2), and although it accounts for only 15%-20% of all breast cancers, it is the deadliest of them, with a five-year survival rate of 77%, a five-year survival rate of 93% for other types of breast cancer, and more than 30% of patients affected by chemotherapy resistance.
is therefore urgently needed for new therapies and companion biomarkers (a biomarker used in combination with specific therapies that can help predict possible reactions or severe toxicity).
In a new study published August 21 in the journal Nature Communications, researchers at the Princess Margaret Cancer Center in Canada have identified a promising new treatment strategy available with biomarkers that are expected to be used to identify patients who benefit most from treatment for more accurate targeted treatment.
source: Previous studies by Nature Communications have shown that triple-negative breast cancer cells have higher glycolysis and lower phosphate oxide than other cancer cell subtypes, while glucose transport protein 1 (GLUT1) plays a key role in regulating the metabolism of triple-negative breast cancer cells, with higher expression of GLUT1 in triple-negative breast cancer.
researchers treated 17 triple-negative breast cancer cell linees using the small molecule GLUT1 inhibitor BAY-876, where significant growth inhibition was observed in 11 cell lineages (see figure below).
Source:Nature Communications After analyzing differences in gene expression in BAY-876-sensitive and drug-resistant cell line, the researchers identified eight proteins that were significantly associated with the BAY-876 response, with levels of retinal cytoblastoma tumor suppression protein (RB1) most associated with triple-negative breast cancer cell sensitivity to BAY-876, while RB1-negative cells were not sensitive to GTUR1 inhibition.
this suggests that RB1 protein levels can be used as biomarkers of bay-876 treatment response in the triple-negative breast cancer cell line and could be used in the future to distinguish between therapy responders and non-responders.
the correlation between RB1 protein levels and the sensitivity of triple-negative breast cancer cell line to BAY-876 (Source: Nature Communications) Co-author Dr Cheryl Arrowsmith believes that matching the right patient to the right drug is a major challenge for cancer research and treatment.
" the more we know about the molecular complexity of cancer cells, the more accurately they can be targeted.
, the more anti-cancer drugs that match specific changes in cancer cells build up, the greater the chance that the cancer will be cured.
," she added.
reference: 1 s Qin Wu et al. GLUT1 addion blocks growth of RB1-positive triple negative breast cancer. Nature Communications (2020) 2 s Duffy, M. J. et al. Companion biomarkers: paving the pathway to the posted treatment for cancer. Clinical chemistry (2013) 3 s Developing precise medicines for triple negative breast cancer (Source: MedicalXpress)